Loading...
XNAS
ACAD
Market cap3.71bUSD
Jun 16, Last price  
22.14USD
1D
1.98%
1Q
28.13%
Jan 2017
-23.23%
IPO
234.95%
Name

ACADIA Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
16.36
P/S
3.87
EPS
1.35
Div Yield, %
—
Shrs. gr., 5y
2.48%
Rev. gr., 5y
23.08%
Revenues
958m
+31.85%
10,956,3008,133,0007,555,0001,590,0006,399,00042,135,0002,067,0004,907,0001,145,000120,00061,00017,331,000124,901,000223,807,000339,076,000441,755,000484,145,000517,235,000726,437,000957,797,000
Net income
226m
P
-34,135,100-45,048,000-56,390,000-64,244,000-45,145,00015,139,000-22,765,000-20,849,000-37,948,000-92,475,000-164,443,000-271,393,000-289,403,000-245,192,000-235,259,000-281,584,000-167,870,000-215,975,000-61,286,000226,451,000
CFO
158m
+844.31%
-20,262,600-41,418,000-54,926,000-64,869,000-13,727,000-10,703,000-19,897,000-21,633,000-31,769,000-66,434,000-121,795,000-210,408,000-217,857,000-167,470,000-151,130,000-136,166,000-125,660,000-114,035,00016,702,000157,719,000
Earnings
Aug 04, 2025

Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
URL
https://acadia.com/
IPO date
May 27, 2004
Employees
540
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
957,797
31.85%
726,437
40.45%
517,235
6.83%
Cost of revenue
385,090
799,816
740,831
Unusual Expense (Income)
NOPBT
572,707
(73,379)
(223,596)
NOPBT Margin
59.79%
Operating Taxes
31,624
10,250
2,531
Tax Rate
5.52%
NOPAT
541,083
(83,629)
(226,127)
Net income
226,451
-469.50%
(61,286)
-71.62%
(215,975)
28.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,845
25,129
8,199
BB yield
-0.22%
-0.49%
-0.32%
Debt
Debt current
9,958
9,405
9,305
Long-term debt
94,032
105,005
105,390
Deferred revenue
Other long-term liabilities
18,056
15,147
9,074
Net debt
(652,003)
(330,225)
(315,098)
Cash flow
Cash from operating activities
157,719
16,702
(114,035)
CAPEX
(523)
(40,050)
Cash from investing activities
(30,538)
31,998
73,241
Cash from financing activities
6,845
25,129
8,199
FCF
546,764
(78,502)
(212,053)
Balance
Cash
755,993
438,865
416,823
Long term investments
5,770
12,970
Excess cash
708,103
408,313
403,931
Stockholders' equity
(2,204,078)
(2,430,797)
(2,370,510)
Invested Capital
3,006,922
2,934,904
2,841,620
ROIC
18.21%
ROCE
71.33%
EV
Common stock shares outstanding
166,362
163,819
161,683
Price
18.35
-41.39%
31.31
96.67%
15.92
-31.79%
Market cap
3,052,743
-40.48%
5,129,173
99.27%
2,573,993
-31.29%
EV
2,400,740
4,798,948
2,258,895
EBITDA
578,366
(67,827)
(221,570)
EV/EBITDA
4.15
Interest
6,610
Interest/NOPBT